Abbott licenses Kowa's pitavastatin for additional markets
This article was originally published in Scrip
Executive Summary
Abbott Laboratories has extended its territorial rights to Kowa's hypolipaemic, pitavastatin, to Australia and New Zealand, where the US firm will exclusively market the product.